What You Need to Know About AbbVie's Surprisingly Strong Q1 Earnings

What You Need to Know About AbbVie's Surprisingly Strong Q1 Earnings

Source: 
Motley Fool
snippet: 

AbbVie (NYSE: ABBV) raised concerns among investors the last time it delivered quarterly results. The drugmaker's January report showed it had missed analysts' estimates on both the top and bottom lines in the fourth quarter, after getting surprised somewhat by its rivals' aggressive pricing of biosimilars to its top-selling treatment, Humira, in Europe.